Lexicon Pharmaceuticals Revenue and Competitors

Claim your profile

Houston, TX USA

Location

$448.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Lexicon Pharmaceuticals's estimated annual revenue is currently $483k per year.(i)
  • Lexicon Pharmaceuticals's estimated revenue per employee is $1,750
  • Lexicon Pharmaceuticals's total funding is $448.5M.
  • Lexicon Pharmaceuticals's current valuation is $513.7M. (January 2022)

Employee Data

  • Lexicon Pharmaceuticals has 276 Employees.(i)
  • Lexicon Pharmaceuticals grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$22.1M11020%N/AN/A
#2
$5.4M6523%N/AN/A
#3
$62.5M0N/AN/AN/A
#4
$3.9M4731%N/AN/A
#5
$3.2M170%$48.2MN/A
#6
$78.4M39019%N/AN/A
#7
$19.5M9759%N/AN/A
#8
$75.2M3741%N/AN/A
#9
$4.4M53-2%N/AN/A
#10
$5.8M2916%N/AN/A

Lexicon Genetics Incorporated is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover the physiological functions and medical uses of genes. The Company's gene function discoveries fuel therapeutic discovery programs in cardiovascular disease, diabetes, obesity, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and further develop its discoveries.

keywords:N/A

$448.5M

Total Funding

276

Number of Employees

$483k

Revenue (est)

10%

Employee Growth %

$513.7M

Valuation

N/A

Accelerator

Lexicon Pharmaceuticals News

2022-03-30 - Lexicon, BridgeBio, Esperion, Pfizer, More Celebrate Wins at ...

Lexicon Pharmaceuticals shared positive data from its Phase III SCORED study on sotagliflozin in reducing cardiovascular death,...

2022-03-30 - ACC: Lexicon hopes sotagliflozin cardio data will set its drug ...

Three years after losing the Type 1 bid, Lexicon has not given up on an approval in that indication, Granowitz said. PharmaSGLT2heart failureheart attackstroke...

2022-03-30 - Lexicon Welcomes New Guidelines for the Management of ...

THE WOODLANDS, Texas, April 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) welcomes new guidelines for the...

2013-09-27 - New venture philanthropy initiative will invest in early-stage treatments for Duchenne

CureDuchenne Ventures has already made its first investment in Lexicon Pharmaceuticals. Woodlands, Texas-based Lexicon is running clinical trials of an experimental drug, LX2931, for rheumatoid arthritis but is apparently also exploring the drug’s potential to initiate muscle regeneration in mou ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75.5M280N/AN/A
#2
$75.5M28013%N/A
#3
$46.3M2909%N/A
#4
$35M29813%N/A
#5
$99.2M32418%N/A